Skip to main content
Figure 2 | BMC Infectious Diseases

Figure 2

From: A historically-controlled Phase III study in adults to characterize the acceptability of a process change for manufacturing inactivated quadrivalent influenza vaccine

Figure 2

Seroprotection rates 21 days after QIV (A) or TIV (B) in the per-protocol immunogenicity cohort . QIV, inactivated quadrivalent influenza vaccine; TIV, inactivated trivalent influenza vaccine; Seroprotection rate defined as proportion with post-vaccination titer ≥1:40; European Union Committee for Medicinal Products for Human Use (CHMP) licensure threshold for seroprotection rate: ≥70% in the 18–60 years group, and ≥60% in the >60 years group [17].

Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us